Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory cytokines in two cohorts of SCLC patients before and during treatment with chem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Hardy-Werbin, Max, Rocha, Pedro, Arpi, Oriol, Taus, Álvaro, Nonell, Lara, Durán, Xavier, Villanueva, Xavier, Joseph-Pietras, Deborah, Nolan, Luke, Danson, Sarah, Griffiths, Richard, Lopez-Botet, Miguel, Rovira, Ana, Albanell, Joan, Ottensmeier, Christian, Arriola, Edurne
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492977/
https://ncbi.nlm.nih.gov/pubmed/31069160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1593810
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados